Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical DataCompany Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA
The FDA (drug regulator) said Grace Therapeutics' medicine looks safe and works well—no big problems found. This is a green light as the company works toward getting official approval to sell it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.